NFX vs. ROQ, MTFB, DEST, BSFA, RENE, PYC, SALV, OBD, OCTP, and OVB
Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Roquefort Therapeutics (ROQ), Motif Bio (MTFB), Destiny Pharma (DEST), BSF Enterprise (BSFA), ReNeuron Group (RENE), Physiomics (PYC), SalvaRx Group (SALV), Oxford BioDynamics (OBD), Oxford Cannabinoid Technologies (OCTP), and Ovoca Bio (OVB). These companies are all part of the "biotechnology" industry.
Nuformix vs.
Roquefort Therapeutics (LON:ROQ) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment, valuation and community ranking.
Nuformix has lower revenue, but higher earnings than Roquefort Therapeutics. Nuformix is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nuformix received 68 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users.
Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Nuformix has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.
In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.
Nuformix has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Nuformix's return on equity of -5.68% beat Roquefort Therapeutics' return on equity.
1.7% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 60.4% of Roquefort Therapeutics shares are held by company insiders. Comparatively, 12.4% of Nuformix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Nuformix beats Roquefort Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Nuformix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuformix Competitors List
Related Companies and Tools
This page (LON:NFX) was last updated on 2/23/2025 by MarketBeat.com Staff
Free NFX Stock Alerts